The point at which doctors assess biomarkers of mesothelioma patients’ response to a combination of chemotherapy and immunotherapy is crucial to obtaining a clear picture of…

Immunotherapy may be the way to tackle malignant pleural mesothelioma (MPM) after relapse, a new Phase 2 trial suggests. Using Opdivo (nivolumab) alone or in combination with…

Cell Medica will begin manufacturing WT1-TCR cell therapy for solid tumors that have been difficult to treat with conventional therapies, such as mesothelioma and ovarian cancer. Cell…

Adding nintedanib to chemotherapy led to a 64 percent increase in the time it took for mesothelioma patients’ disease to progress, compared with chemo alone,…

The calcium-binding protein calretinin is useful as a blood-based biomarker with high sensitivity to detect malignant mesothelioma, finds a study, “Calretinin as a blood-based biomarker for mesothelioma,” that…

A study has tried to overcome the challenges in the diagnosis of patients with malignant pleural mesothelioma (MPM) through the detection of two biomarkers in pleural…

Whole exome sequencing of asbestos-induced mouse models of malignant mesothelioma (MM) is a genuine representation of human mesothelioma and is a valuable tool for further…

Last year’s progress in preventing, diagnosing and treating all forms of lung cancer, including mesothelioma,  is summarized in the second annual edition of the report, “Scientific Advances…